The archive · Health & Care · Strategic decision · 2013-2026
Doctolib's primary-care platform bet: 12 loss-making years, then profit and UK expansion
Doctolib bet doctors would rent booking SaaS and patients adopt the free app; after 12 loss-making years it turned profitable in 2025, then bought UK's Medicus.
Doctolib
What the business is
Doctolib is a health-tech SaaS platform: practices use it to manage appointments, patient documents, notes and invoices, with telehealth and secure messaging add-ons, while patients get a free booking app; it operates in France, Germany, Italy, the Netherlands and, since May 2026, the UK.
How it started
Founded in France in 2013, Doctolib began as an online booking platform connecting doctors and patients, sold to independent practices as software that removed phone queues and paper diaries. TechCrunch describes the product as SaaS for doctors and medical workers to tackle administrative tasks, with patients on the free side of the network.
What happened
Covid-19 turned Doctolib into essential national infrastructure: the French government promoted it for vaccination and test bookings and millions of people created accounts. By March 2022 it had 60 million users across France, Germany and Italy and 300,000 healthcare workers, and raised €500 million ($549 million) in equity and debt at a €5.8 billion ($6.4 billion) valuation - at the time the highest of any French startup - led by Eurazeo with Bpifrance and General Atlantic, planning to grow from 2,500 to 6,000 staff. It kept losing money while expanding products (Doctolib Médecin, Doctolib Team, telehealth, encryption via Tanker) and markets; Clubic puts its 2024 EBITDA at roughly minus €54 million.
How it ended up
In late October 2025 co-founder Stanislas Niox-Chateau told BFMTV that Doctolib had become profitable for the first time since its 2013 founding, saying profitability lets the company be master of its own destiny. On 2026-05-06 it announced the acquisition of Medicus, maker of practice-management software for NHS general practitioners, with plans to invest over £100 million, hire 150 people and open a UK R&D centre - its fifth European market. Still private and expanding.
Background
Founded in France in 2013, Doctolib's original bet was that independent doctors would pay for software to run appointment booking while patients used the app for free - a two-sided network in primary care. The product started as a booking platform and grew into a practice operating system with documents, patient history, notes, invoicing, telehealth and secure team messaging.
Covid-19 made Doctolib essential: the French government steered vaccination and test booking through the platform, creating millions of accounts almost overnight. By March 2022 it counted 60 million users in France, Germany and Italy and 300,000 healthcare workers, and raised €500 million at a €5.8 billion ($6.4 billion) valuation, then the highest of any French startup, with Eurazeo, Bpifrance and General Atlantic. The company kept spending on products and European expansion while losses continued - Clubic reports 2024 EBITDA of roughly minus €54 million.
The long bet finally flipped in late October 2025, when co-founder Stanislas Niox-Chateau told BFMTV that Doctolib had become profitable for the first time since its creation, with about 50 million users in France, 80 million across Europe and 400,000 health professionals. On 2026-05-06 it announced the acquisition of Medicus, whose software runs NHS general practices, with over £100 million of planned UK investment, making Britain its fifth market after France, Germany, Italy and the Netherlands, and it is adding AI products aimed at patients and caregivers.
What has to be true
- It bet on the supply side first: selling booking SaaS to independent doctors, whose adoption then pulls in patients, instead of building a consumer app and hoping doctors would join.
- Covid turned the bet into a national habit: government-promoted vaccination and test booking brought millions of users and made Doctolib the default way to see a doctor in France.
- It carried years of losses deliberately, reinvesting into product breadth (documents, invoicing, telehealth, messaging, encryption) and acquisitions across Germany, Italy and the Netherlands.
- The resulting network - 400,000 health professionals and 80 million users - is what finally made subscriptions profitable in 2025 and funds new entries such as the UK.
What can be applied
Losses are only worth carrying while they buy two-sided network scale: Doctolib's 12 years of red ink built the doctor-patient default that finally made its subscriptions profitable.
Aftermath
As of 2026-05-06 Doctolib is running and scaling: profitable for the first time since its 2013 founding, with roughly 50 million users in France, 80 million across Europe, 400,000 health professionals and about 3,000 staff. Its May 2026 acquisition of Medicus opens the UK - its fifth market after France, Germany, Italy and the Netherlands - backed by over £100 million of planned investment, and it is adding AI products for patients and caregivers. The company remains private; its last primary round, in March 2022, valued it at €5.8 billion, and no IPO or shutdown has been announced.
Sources
- Healthcare tech platform Doctolib reaches $6.4 billion valuation
- 12 ans après son lancement, l'iconique Doctolib tourne enfin la page des pertes !
- Doctolib renforce sa présence au Royaume-Uni
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card